Literature DB >> 10392611

Novel adjuvants currently in clinical testing November 2-4, 1998, Fondation Mérieux, Annecy, France: a meeting sponsored by the World Health Organization.

T Aguado1, H Engers, T Pang, R Pink.   

Abstract

Mesh:

Substances:

Year:  1999        PMID: 10392611     DOI: 10.1016/s0264-410x(99)00021-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  6 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Technologies to improve immunisation safety.

Authors:  C J Clements; M T Aguado; L Jódar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 4.  Delivery technologies for human vaccines.

Authors:  Philippe Moingeon; Charles de Taisne; Jeffrey Almond
Journal:  Br Med Bull       Date:  2002       Impact factor: 4.291

5.  A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.

Authors:  Blaise Genton; Gerd Pluschke; Lukas Degen; Andreas R Kammer; Nicole Westerfeld; Shinji L Okitsu; Sandro Schroller; Penelope Vounatsou; Markus M Mueller; Marcel Tanner; Rinaldo Zurbriggen
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

Review 6.  Squalene emulsions for parenteral vaccine and drug delivery.

Authors:  Christopher B Fox
Journal:  Molecules       Date:  2009-09-01       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.